Citations

Clear

7552 citation(s) found for "Ho, Matthew".

A Teenage Girl With Aseptic Meningitis and Unilateral Blurry Vision
Starr, Matthew R. , Smith, Wendy M. , Starr, Matthew R

Mayo Clinic

JAMA Ophthalmology | July 6, 2017 | Volume: 135 | Issue: 10 | Pages: 1111

10.1001/jamaophthalmol.2017.0747 | PMID 28687842 Get It

Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience
Gamez, Mauricio E. , Jeans, Elizabeth B. , Hinni, Michael L., Moore, Eric J. , Young, Geoffrey D., McGee, L.A. , Buras, Matthew , Patel, Samir H. , Moore, Eric, Young, Geoffrey, Ma, Daniel, McGee, Lisa, Daniel, J. , Buras, Matthew R

Mayo Clinic

The Laryngoscope | July 6, 2017 | Volume: 128 | Issue: 2 | Pages: 373-377

10.1002/lary.26725 | PMID 28681992 Get It

Objectives/HypothesisSarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes.Study DesignRetrospective study. Median follow‐up 45 months.MethodsThere were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression‐free survival (PFS), and local control (LC) were conducted using the Kaplan‐Meier method.ResultsThe majority of patients were elderly males (92%) with a smoking history (74%) presenting with early‐stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high‐risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3–75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five‐year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II–IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039).ConclusionsSarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early‐stage tumors are treated appropriately with single‐modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.Level of Evidence4. Laryngoscope, 128:373–377, 2018
Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
Domingo‐Musibay, Evidio , Heun, James M., Nevala, Wendy K. , Callstrom, Matthew R. , Atwell, Thomas D. , Callstrom, Matthew, Atwell, Thomas, Galanis, Evanthia , Erickson, Lori A. , Markovic, Svetomir N.

Mayo Clinic

The Oncologist | July 6, 2017 | Volume: 22 | Issue: 9 | Pages: 1026-e93

10.1634/theoncologist.2017-0060 | PMID 28679643 Get It

Abstract Lessons Learned Percutaneous thermal ablation combined with in situ granulocyte-macrophage colony-stimulating factor cytokine therapy was technically feasible and well tolerated. No significant clinical or immunologic responses were seen. Background Melanoma tumor-derived heat-shock proteins (HSPs) and HSP-peptide complexes can elicit protective antitumor responses. The granulocyte-macrophage colony-stimulating factor (GM-CSF) chemokine can also promote uptake and processing by professional antigen presenting cells (APCs). On this basis, we designed a pilot study of percutaneous thermal ablation as a means to induce heat-shock protein vaccination plus GM-CSF to determine safety and preliminary antitumor activity of this combination. Materials and Methods This study was designed to assess overall safety of percutaneous ablation combined with GM-CSF for unresectable, metastatic melanoma including uveal and mucosal types. All patients received heat-shock therapy (42°C for 30 minutes), then received one of three treatments: (a) intralesional GM-CSF (500 mcg standard dose); (b) radiofrequency ablation (RFA) + GM-CSF; or (c) cryoablation plus GM-CSF. The primary endpoint of the study was the induction of endogenous HSP70 and melanoma-specific cytotoxic T lymphocytes (CTL). Results Nine patients (three per study arm) were enrolled. No dose-limiting toxicity was observed as specified per protocol. All patients developed progressive disease and went on to receive alternative therapy. Median overall survival (OS) was 8.2 months (95% confidence interval [CI] 2–17.2). The study was not powered to detect a difference in clinical outcome among treatment groups. Conclusion Percutaneous thermal ablation plus GM-CSF was well tolerated, technically feasible, and demonstrated an acceptable adverse event profile comparable to conventional RFA and cryoablation. While HSP70 was induced following therapy, the degree of HSP70 elevation was not associated with clinical outcome or induced CTL responses. While percutaneous thermal ablation plus GM-CSF combinations including checkpoint inhibitors could be considered in future studies, the use of GM-CSF remains experimental and for use in the context of clinical trials.
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia, X. , Bose, Ron , Gao, Feng , Telli, Melinda L. , Kimmick, Gretchen , Russell, Christy , Cobleigh, Melody , Forero, Andres , Anders, Carey K. , Thomas, Shana , Anderson, J. L. , Bumb, Caroline, Banks, Kimberly C. , Bryce, Richard , Lalani, Alshad S. , Pfeifer, John D. , Hayes, Daniel F. , Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Al‐Kateb, Hussam , Freedman, Rachel A. , Winer, Eric P. , Naughton, Michael J. , Goetz, Matthew P. , Tripathy, Debu , Pluard, Timothy , Niravath, Polly Ann , Anderson, Jill, Lanman, Richard B. , Ellis, Matthew J. , Banks, Kimberly C , Gao, Feng , Telli, Melinda L

Mayo Clinic

Clinical Cancer Research | July 5, 2017 | Volume: 23 | Issue: 19 | Pages: 5687-5695

10.1158/1078-0432.ccr-17-0900 | PMID 28679771 Get It

Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2mut detection. Experimental Design: Tumor tissue positive for HER2mut was required for eligibility. Neratinib was administered 240 mg daily with prophylactic loperamide. ctDNA sequencing was performed retrospectively for 54 patients (14 positive and 40 negative for tumor HER2mut). Results: Nine of 381 tumors (2.4%) sequenced centrally harbored HER2mut (lobular 7.8% vs. ductal 1.6%; P = 0.026). Thirteen additional HER2mut cases were identified locally. Twenty-one of these 22 HER2mut cases were estrogen receptor positive. Sixteen patients [median age 58 (31–74) years and three (2–10) prior metastatic regimens] received neratinib. The CBR was 31% [90% confidence interval (CI), 13%–55%], including one CR, one PR, and three SD ≥24 weeks. Median PFS was 16 (90% CI, 8–31) weeks. Diarrhea (grade 2, 44%; grade 3, 25%) was the most common adverse event. Baseline ctDNA sequencing identified the same HER2mut in 11 of 14 tumor-positive cases (sensitivity, 79%; 90% CI, 53%–94%) and correctly assigned 32 of 32 informative negative cases (specificity, 100%; 90% CI, 91%–100%). In addition, ctDNA HER2mut variant allele frequency decreased in nine of 11 paired samples at week 4, followed by an increase upon progression. Conclusions: Neratinib is active in HER2mut, nonamplified MBC. ctDNA sequencing offers a noninvasive strategy to identify patients with HER2mut cancers for clinical trial participation. Clin Cancer Res; 23(19); 5687–95. ©2017 AACR.
Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor
Rose, Peter S. , Bakri, Karim , Wagner, Eric R. , Yaszemski, Michael J. , Sim, Franklin H. , Moran, Steven L. , Houdek, Matthew T. , Wagner, Eric R

Mayo Clinic

Journal of Bone and Joint Surgery | July 4, 2017 | Volume: 99 | Issue: 13 | Pages: e69

10.2106/jbjs.16.01458 | PMID 28678130 Get It

Background: Following resection of malignant tumors of the spine and pelvis, reconstructive surgeons often face large structural defects. Unlike reconstruction in the extremities, wherein a free vascularized fibular graft (FVFG) is a highly utilized option for segmental osseous reconstruction, there are limited data on the use of an FVFG in the spine and pelvis. The aim of this study was to review our institution’s experience with reconstruction with use of an FVFG following oncological resection in the spine and pelvis. Methods: We reviewed 24 cases involving the use of an FVFG in reconstruction of segmental osseous defects of the spine and pelvis following oncological resection from 2000 to 2015. The cohort consisted of 12 male and 12 female patients with a mean age of 37 years and a mean follow-up of 5 years. Fifty-four percent of the reconstructions were spinopelvic or sacropelvic. Results: The overall 2, 5, and 10-year rate of survival was 76%, 55%, and 37%, respectively. With regard to disease-free survival, the overall 2, 5, and 10-year rate was 81%, 72%, and 48%. The overall rate of union was 86%, with a mean time to union of 7 months. Complications were common, with 83% of the patients sustaining at least 1 postoperative complication. Following the procedure, the mean Musculoskeletal Tumor Society rating was 53%. Conclusions: An FVFG provides a durable means of reconstruction of osseous defects in the spine and pelvis. Although patient function was acceptable following these large reconstructions, the rate of postoperative complications was high. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
The Evolution of the Cup-Cage Technique for Major Acetabular Defects
Sculco, Peter K. , Hanssen, Arlen D. , Lewallen, David G. , Ledford, Cameron K. , Abdel, Matthew P.

Mayo Clinic

Journal of Bone and Joint Surgery | July 4, 2017 | Volume: 99 | Issue: 13 | Pages: 1104-1110

10.2106/jbjs.16.00821 | PMID 28678123 Get It

Background: Complex acetabular reconstruction for major bone loss can require advanced methods such as the use of a cup-cage construct. The purpose of this study was to review outcomes after the initial development of the cup-cage technique and the subsequent evolution to the use of a half cup-cage construct. Methods: We performed a retrospective, single-center review of 57 patients treated with cup-cage reconstruction for major acetabular bone loss. All patients had major acetabular defects graded as Paprosky Type 2B through 3B, with 34 (60%) having an associated pelvic discontinuity. Thirty patients received a full cup-cage construct and 27, a half cup-cage construct. The mean follow-up was 5 years. Results: Both the full and half cup-cage cohorts demonstrated significantly improved Harris hip score (HHS) values, from 36 to 72 at a minimum of 2 years of follow-up (p < 0.05). Early construct migration occurred in 4 patients, with stabilization prior to 2-year follow-up in all but 1 patient. Incomplete, zone-3, nonprogressive acetabular radiolucencies were observed in 2 (7%) of the full cup-cage constructs and 6 (22%) of the half cup-cage constructs. One patient with a full cup-cage construct underwent re-revision of the acetabular component for progressive migration and aseptic loosening. Short-term survivorship free from re-revision for any cause or reoperation was 89% (83% and 96% for full and half cup-cage cohorts, respectively). Conclusions: Both full and half cup-cage constructs demonstrated successful clinical outcomes and survivorship in the treatment of major acetabular defects and pelvic discontinuity. Each method is utilized on the basis of individual intraoperative findings, including the extent and pattern of bone loss, the quality and location of host bone remaining after preparation, and the presence of pelvic discontinuity. Longer-term follow-up is required to understand the durability of these constructs in treating major acetabular defects and pelvic discontinuity. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, Lori , Pasquini, Marcelo C. , Martens, Michael J. , Brazauskas, Ruta , Zhu, Xiaochun , Adekola, Kehinde , Aljurf, Mahmoud , Ballen, Karen K. , Baron, Frédéric , Beitinjaneh, Amer , Cahn, Jean‐Yves, Carabasi, Mathew, Chen, Yi‐Bin , Ciurea, Stefan O. , Copelan, Edward A. , D’Souza, Anita , Edwards, John , Foran, James M. , Freytes, César O. , Fung, Henry C., Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Ho, Vincent T. , Jakubowski, Ann A. , Luskin, Marlise R. , Martino, Rodrigo , Olin, Rebecca L. , Olsson, Richard F. , Pawarode, Attaphol , Peres, Edward, Rezvani, Andrew R. , Rizzieri, David A. , Schouten, Harry C. , Sabloff, Mitchell , Seftel, Matthew D. , Seo, Sachiko , Sorror, Mohamed L. , Wirk, Baldeep , Wood, William A. , Bajel, Ashish R. , Battiwalla, Minoo , Cahn, Jean‐Yves , Chhabra, Saurabh , Gale, Robert Peter , Giralt, Sergio , Lazarus, Hillard M. , Luskin, Marlise R , Maziarz, Richard Thomas , McCarthy, Philip L. , Nishihori, Taiga , Savani, Bipin N. , Szer, Jeff , Artz, Andrew , D'Souza, Anita , Olsson, Richard F , Martino, Rodrigo , Muffly, Lori , Sabloff, Mitchell , Martens, Michael J , Sorror, Mohamed , Wood, William A

Mayo Clinic

Blood | July 3, 2017 | Volume: 130 | Issue: 9 | Pages: 1156-1164

10.1182/blood-2017-03-772368 | PMID 28674027 Get It

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.
Intra‐articular injection of a substance P inhibitor affects gene expression in a joint contracture model
Lewallen, Eric A. , An, Kai‐Nan, Grill, Diane E. , Steinmann, Scott P. , Yao, Jie , Salib, Christopher G. , Trousdale, William H. , Reina, Nicolas , Kremers, Hilal Maradit , Lewallen, David G. , Wijnen, André J. van , Sanchez-Sotelo, Joaquin, Yao, Jie J, Kremers, Hilal M, van Wijnen, Andre J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , An, Kai‐Nan , Abdel, Matthew P. , Maradit Kremers, Hilal

Mayo Clinic

Journal of Cellular Biochemistry | July 3, 2017 | Volume: 119 | Issue: 2 | Pages: 1326-1336

10.1002/jcb.26256 | PMID 28671282 Get It

AbstractSubstance P (SP), a neurotransmitter released after injury, has been linked to deregulated tissue repair and fibrosis in musculoskeletal tissues and other organs. Although SP inhibition is an effective treatment for nausea, it has not been previously considered as an anti‐fibrotic therapy. Although there are extensive medical records of individuals who have used SP antagonists, our analysis of human registry data revealed that patients receiving these antagonists and arthroplasty are exceedingly rare, thus precluding a clinical evaluation of their potential effects in the context of arthrofibrosis. Therefore, we pursued in vivo studies to assess the effect of SP inhibition early after injury on pro‐fibrotic gene expression and contractures in an animal model of post‐traumatic joint stiffening. Skeletally mature rabbits (n = 24) underwent surgically induced severe joint contracture, while injected with either fosaprepitant (a selective SP antagonist) or saline (control) early after surgery (3, 6, 12, and 24 h). Biomechanical testing revealed that differences in mean contracture angles between the groups were not statistically significant (P = 0.27), suggesting that the drug neither mitigates nor exacerbates joint contracture. However, microarray gene expression analysis revealed that mRNA levels for proteins related to cell signaling, pro‐angiogenic, pro‐inflammatory, and collagen matrix production were significantly different between control and fosaprepitant treated rabbits (P < 0.05). Hence, our study demonstrates that inhibition of SP alters expression of pro‐fibrotic genes in vivo. This finding will motivate future studies to optimize interventions that target SP to reduce the formation of post‐traumatic joint contractures.
EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review
Mehner, Christine , Oberg, Ann L. , Goergen, Krista M., Kalli, Kimberly R., Goode, Ellen L. , Keeney, Gary L., Jatoi, Aminah , Radisky, Evette S. , Radisky, Derek C. , Maurer, Matthew J. , Nassar, Aziza , Radisky, Evette S

Mayo Clinic

Genes & Cancer | July 1, 2017 | Volume: 8 | Issue: 5-6 | Pages: 589-599

10.18632/genesandcancer.142 | PMID 28740577 Get It

Quality measurement for rhinosinusitis: a review from the Quality Improvement Committee of the American Rhinologic Society
Rudmik, Luke , Mattos, José L. , Schneider, John S. , Manes, Peter R., Stokken, Janalee K., Lee, Jivianne, Schlosser, Rodney J. , Reh, Douglas D., Setzen, Michael, Stokken, Janalee K. , Lee, Jivianne T. , Higgins, Thomas S , Soler, Zachary M. , Schlosser, Rodney J , Carlson, Matthew L , Mattos, Jose

Mayo Clinic

International Forum of Allergy & Rhinology | June 30, 2017 | Volume: 7 | Issue: 9 | Pages: 853-860

10.1002/alr.21983 | PMID 28665549 Get It

BackgroundMeasuring quality outcomes is an important prerequisite to improve quality of care. Rhinosinusitis represents a high value target to improve quality of care because it has a high prevalence of disease, large economic burden, and large practice variation. In this study we review the current state of quality measurement for management of both acute (ARS) and chronic rhinosinusitis (CRS).MethodsThe major national quality metric repositories and clearinghouses were queried. Additional searches included the American Academy of Otolaryngology–Head and Neck Surgery database, PubMed, and Google to attempt to capture any additional quality metrics.ResultsSeven quality metrics for ARS and 4 quality metrics for CRS were identified. ARS metrics focused on appropriateness of diagnosis (n = 1), antibiotic prescribing (n = 4), and radiologic imaging (n = 2). CRS quality metrics focused on appropriateness of diagnosis (n = 1), radiologic imaging (n = 1), and measurement of patient quality of life (n = 2). The Physician Quality Reporting System (PQRS) currently tracks 3 ARS quality metrics and 1 CRS quality metric. There are no outcome‐based rhinosinusitis quality metrics and no metrics that assess domains of safety, patient‐centeredness, and timeliness of care.ConclusionsThe current status of quality measurement for rhinosinusitis has focused primarily on the quality domain of efficiency and process measures for ARS. More work is needed to develop, validate, and track outcome‐based quality metrics along with CRS‐specific metrics. Although there has been excellent work done to improve quality measurement for rhinosinusitis, there remain major gaps and challenges that need to be considered during the development of future metrics.